emergency

Ulipristal acetate (CDB-2914) is an orally bioavailable selective progesterone receptor modulator with anti-progesterone activity. It binds to the progesterone receptor (PR), inhibiting PR-mediated gene expression and interfering with progesterone activity in the reproductive system, potentially suppressing the growth of uterine leiomyomatosis. Additionally, ulipristal can be used as emergency contraception by inhibiting or delaying ovulation and affecting endometrial tissue.

Ulipristal is a selective SPRM for emergency contraception after an unprotected intercourse or contraceptive failure.

DC-174 is an orally effective small molecule inhibitor of snake venom metalloproteinases (SVMPs) belonging to the hydroxamic acid class. As a candidate molecule optimized from the lead compound XL-784 through structure-activity relationship studies, it broadly inhibits the SVMP enzymatic activity of various snake venoms (e.g., saw-scaled viper, western diamondback rattlesnake, Malayan pit viper, etc.) with IC50 values below 10 nM by chelating the zinc ion in the SVMP active site via its hydroxamic acid group. It also neutralizes snake venom-induced procoagulant toxicity. Pharmacokinetic studies show that DC-174 reaches peak blood concentration approximately 30 minutes after oral administration but has a short half-life (approx. 1.41 hours). Optimized multi-dose regimens can prolong effective exposure time, demonstrating significant survival protection effects in severe snakebite mouse models, thus positioning it as a promising lead compound for developing oral emergency snakebite treatments.

Mivacurium dichloride (Mivacurium chloride) is a non-depolarising, rapid neuromuscular blocker of short duration, used therefore as anesthetic, to provide skeletal muscle relaxation in minor surgical operations, in emergency surgical procedures of short to intermediate duration and during intubation of the trachea.

Bamlanivimab, an Anti-Human SARS-CoV-2 monoclonal antibody (mAb), was the first of its kind to receive Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in November 2020 for COVID-19 treatment. However, its authorization was withdrawn in April 2021 due to emerging SARS-CoV-2 variants resistant to the antibody [1].